Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review
We report a case of a 53-year-old male patient who was diagnosed with anaplastic lymphoma kinase-positive large B-cell lymphoma. A pathological examination showed plasma-cell immunophenotype negative for mature B-lymphocyte markers. The patient received three cycles of an “alectinib + Vincristine +...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1480880/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592438079782912 |
|---|---|
| author | Hongxia Wang Junjun Bai Bei Zhang Zhixin Pei Yingxin Zhao Jingjing Gu Zhiyu Fang Miaomiao Liu Xun Liang Qinglin Song |
| author_facet | Hongxia Wang Junjun Bai Bei Zhang Zhixin Pei Yingxin Zhao Jingjing Gu Zhiyu Fang Miaomiao Liu Xun Liang Qinglin Song |
| author_sort | Hongxia Wang |
| collection | DOAJ |
| description | We report a case of a 53-year-old male patient who was diagnosed with anaplastic lymphoma kinase-positive large B-cell lymphoma. A pathological examination showed plasma-cell immunophenotype negative for mature B-lymphocyte markers. The patient received three cycles of an “alectinib + Vincristine + Rituximab + Cyclophosphamide + Doxorubicin (VRCD) “ regimen. In the fourth cycle, brentuximab vedotin monoclonal antibody treatment was added to increase the efficacy of the treatment. Positron emission tomography-computed tomography and a bone marrow examination were carried out after four cycles, revealing a complete response. Stem cells were successfully harvested. Thus far, the patient has undergone six treatment cycles and successfully received autologous hematopoietic stem cell transplantation. Currently, the patient is receiving maintenance therapy with alectinib and lenalidomide and remains in a favorable clinical condition. |
| format | Article |
| id | doaj-art-dcc97dc9b7c44ee591a497085d4f1f77 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-dcc97dc9b7c44ee591a497085d4f1f772025-01-21T08:37:02ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.14808801480880Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature reviewHongxia Wang0Junjun Bai1Bei Zhang2Zhixin Pei3Yingxin Zhao4Jingjing Gu5Zhiyu Fang6Miaomiao Liu7Xun Liang8Qinglin Song9Department of Hematology, Jiaozuo People’s Hospital, Jiaozuo, Henan, ChinaDepartment of Hematology, Jiaozuo People’s Hospital, Jiaozuo, Henan, ChinaDepartment of Hematology, Jiaozuo People’s Hospital, Jiaozuo, Henan, ChinaDepartment of Hematology, Jiaozuo People’s Hospital, Jiaozuo, Henan, ChinaDepartment of Hematology, Jiaozuo People’s Hospital, Jiaozuo, Henan, ChinaDepartment of Hematology, Jiaozuo People’s Hospital, Jiaozuo, Henan, ChinaDepartment of Hematology, Jiaozuo People’s Hospital, Jiaozuo, Henan, ChinaDepartment of Hematology, Jiaozuo People’s Hospital, Jiaozuo, Henan, ChinaCollege of Resources and Environment, Henan Polytechnic University, Jiaozuo, Henan, ChinaDepartment of Hematology, Jiaozuo People’s Hospital, Jiaozuo, Henan, ChinaWe report a case of a 53-year-old male patient who was diagnosed with anaplastic lymphoma kinase-positive large B-cell lymphoma. A pathological examination showed plasma-cell immunophenotype negative for mature B-lymphocyte markers. The patient received three cycles of an “alectinib + Vincristine + Rituximab + Cyclophosphamide + Doxorubicin (VRCD) “ regimen. In the fourth cycle, brentuximab vedotin monoclonal antibody treatment was added to increase the efficacy of the treatment. Positron emission tomography-computed tomography and a bone marrow examination were carried out after four cycles, revealing a complete response. Stem cells were successfully harvested. Thus far, the patient has undergone six treatment cycles and successfully received autologous hematopoietic stem cell transplantation. Currently, the patient is receiving maintenance therapy with alectinib and lenalidomide and remains in a favorable clinical condition.https://www.frontiersin.org/articles/10.3389/fonc.2024.1480880/fullALK+ LBCLalectinibbortezomiblenalidomideBV monoclonal antibody |
| spellingShingle | Hongxia Wang Junjun Bai Bei Zhang Zhixin Pei Yingxin Zhao Jingjing Gu Zhiyu Fang Miaomiao Liu Xun Liang Qinglin Song Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review Frontiers in Oncology ALK+ LBCL alectinib bortezomib lenalidomide BV monoclonal antibody |
| title | Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review |
| title_full | Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review |
| title_fullStr | Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review |
| title_full_unstemmed | Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review |
| title_short | Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review |
| title_sort | alectinib combined with vrcd and bv monoclonal antibody for the treatment of alk positive large b cell lymphoma a case report and literature review |
| topic | ALK+ LBCL alectinib bortezomib lenalidomide BV monoclonal antibody |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1480880/full |
| work_keys_str_mv | AT hongxiawang alectinibcombinedwithvrcdandbvmonoclonalantibodyforthetreatmentofalkpositivelargebcelllymphomaacasereportandliteraturereview AT junjunbai alectinibcombinedwithvrcdandbvmonoclonalantibodyforthetreatmentofalkpositivelargebcelllymphomaacasereportandliteraturereview AT beizhang alectinibcombinedwithvrcdandbvmonoclonalantibodyforthetreatmentofalkpositivelargebcelllymphomaacasereportandliteraturereview AT zhixinpei alectinibcombinedwithvrcdandbvmonoclonalantibodyforthetreatmentofalkpositivelargebcelllymphomaacasereportandliteraturereview AT yingxinzhao alectinibcombinedwithvrcdandbvmonoclonalantibodyforthetreatmentofalkpositivelargebcelllymphomaacasereportandliteraturereview AT jingjinggu alectinibcombinedwithvrcdandbvmonoclonalantibodyforthetreatmentofalkpositivelargebcelllymphomaacasereportandliteraturereview AT zhiyufang alectinibcombinedwithvrcdandbvmonoclonalantibodyforthetreatmentofalkpositivelargebcelllymphomaacasereportandliteraturereview AT miaomiaoliu alectinibcombinedwithvrcdandbvmonoclonalantibodyforthetreatmentofalkpositivelargebcelllymphomaacasereportandliteraturereview AT xunliang alectinibcombinedwithvrcdandbvmonoclonalantibodyforthetreatmentofalkpositivelargebcelllymphomaacasereportandliteraturereview AT qinglinsong alectinibcombinedwithvrcdandbvmonoclonalantibodyforthetreatmentofalkpositivelargebcelllymphomaacasereportandliteraturereview |